REPAGLINIDE
Obesity &Amp; Overweight
Vincentage Pharma Co., LtdSmall moleculePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Obesity &Amp; Overweight cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ubt251 The United Bio-Technology (Hengqin) Co., Ltd. | Phase 3 | BB |
rn3161 Ikaria Bioscience Pty Ltd | Phase 1/2 | CC |
Liver-Expressed Antimicrobial Peptide 2 University Hospital, Gentofte, Copenhagen | Phase 1/2 | CC |
RIFALDAZINE Vincentage Pharma Co., Ltd | Phase 1 | CC |
PLANTS AND PLANT PARTS, HEMP USDA Beltsville Human Nutrition Research Center | N/A | D |
In-B00009 HK inno.N Corporation | Phase 3 | NR |
Same molecule, other indications
REPAGLINIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →